Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia
Jessica M Salmon, Michael Bots, Eva Vidacs, Kym L Stanley, Peter Atadja, Johannes Zuber, Ricky W Johnstone
Clinical Epigenetics | BMC | Published : 2015
The authors would like to thank Dr D. Carnie for helpful advice and Prof Y. Haupt for the anti-PML antibody. J.M.S. is supported by Cure Cancer Australia. R.W.J. is a Principal Research Fellow of the National Health and Medical Research Council (NHMRC) of Australia and supported by NHMRC Program and Project Grants, Cancer Council Victoria, the Leukaemia Foundation of Australia, and the Victorian Cancer Agency.